Regional myocardial sympathetic denervation precedes the development of left ventricular systolic dysfunction in chronic Chagas' cardiomyopathy.

BACKGROUND: Regional myocardial sympathetic denervation is a conspicuous and early disorder in patients with chronic Chagas' cardiomyopathy (CCC), potentially associated to the progression of myocardial dysfunction OBJECTIVE: To evaluate in a longitudinal study the association between the presence and the progression of regional myocardial sympathetic denervation with the deterioration of global and segmental left ventricular dysfunction in CCC. METHODS: 18 patients with CCC were submitted at initial evaluation and after 5.5 years to rest myocardial scintigraphy with 123Iodo-metaiodobenzylguanidine and 99mTc-sestamibi and to two-dimensional echocardiography to assess myocardial sympathetic denervation, extent of fibrosis, and the left ventricular ejection fraction (LVEF) and wall motion abnormalities. RESULTS: In the follow-up evaluation, compared to the initial one, we observed a significant decrease in LVEF (56 ± 11 to 49% ± 12; P = .01) and increased summed defects scores in the myocardial innervation scintigraphy (15 ± 10 to 20 ± 9; P < .01). The presence of regional myocardial sympathetic denervation in ventricular regions of viable non-fibrotic myocardium presented an odds ratio of 4.25 for the development of new wall motion abnormalities (P = .001). CONCLUSION: Regional and global myocardial sympathetic denervation is a progressive derangement in CCC. In addition, the regional denervation is topographically associated with areas of future development of regional systolic dysfunction in patients with CCC.

The severity of ventricular arrhythmia correlates with the extent of myocardial sympathetic denervation, but not with myocardial fibrosis extent in chronic Chagas cardiomyopathy : Chagas disease, denervation and arrhythmia.

BACKGROUND: To investigate the correlation between the extent of myocardial sympathetic denervation and fibrosis and the presence of degrees of severity of ventricular arrhythmias in chronic Chagas cardiomyopathy (CCC). METHODS: Forty-three CCC patients with left ventricular ejection fraction (LVEF) ≥ 35% were divided into three groups: SVT group-presenting Sustained Ventricular Tachycardia (SVT) (n = 15), NSVT group-exhibiting episodes of non-SVT (NSVT) on 24-h Holter monitoring (n = 11), and Control group-exhibiting neither SVT nor episodes of NSVT (n = 17). The patients underwent SPECT imaging for myocardial sympathetic innervation with 123Iodine-MIBG (MIBG) and myocardial perfusion with 99mTc-Sestamibi (MIBI) for the evaluation of regional myocardial fibrosis. RESULTS: The summed rest perfusion scores were similar in the three groups. The summed difference score between MIBG and MPI images, which evaluated the extent of denervated but viable myocardium, was significantly higher in SVT group (20.0 ± 8.0) as compared with the control group (2.0 ± 5.0, P < .0001) and with the NSVT group (11.0 ± 8.0, P < .05). CONCLUSIONS: The occurrence of ventricular arrhythmias of different degrees of severity correlates quantitatively with the extent of cardiac sympathetic denervation, but not with the extent of fibrosis, suggesting that myocardial sympathetic denervation plays a major role in triggering ventricular arrhythmia in CCC.

Pilot study testing the effect of physical training over the myocardial perfusion and quality of life in patients with primary microvascular angina.

BACKGROUND: Primary microvascular angina (PMA) is a common clinical condition associated to negative impact on quality of life (QOL) and reduced physical capacity. This study aimed at evaluating the effects of aerobic physical training (APT) on myocardial perfusion, physical capacity, and QOL in patients with PMA. METHODS: We investigated 12 patients (53.8 ± 9.7 years old; 7 women) with PMA, characterized by angina, angiographycally normal coronary arteries, and reversible perfusion defects (RPDs) detected on (99m)Tc-sestamibi-SPECT myocardial perfusion scintigraphy (MPS). At baseline and after 4 month of APT, the patients underwent MPS, cardiopulmonary test, and QOL questionnaire. Stress-rest MPS images were visually analyzed by attributing semi-quantitative scores (0 = normal; 4 = absent uptake), using a 17-segment left ventricular model. Summed stress, rest, and difference scores (SDS) were calculated. RESULTS: In comparison to the baseline, in the post-training we observed a significant increase in peak-VO2 (19.4 ± 4.8 and 22.1 ± 6.2 mL·kg(-1)·minute(-1), respectively, P = .01), reduction of SDS (10.1 ± 8.8 and 2.8 ± 4.9, P = .008), and improvement in QOL scores. CONCLUSIONS: Physical training in patients with PMA is associated with reduction of myocardial perfusion abnormalities, increasing of physical capacity, and improvement in QOL. The findings of this hypothesis-generating study suggest that APT can be a valid therapeutic option for patients with PMA.

Substituição do carvedilol pelo propranolol em pacientes com insuficiência cardíaca / Replacement of carvedilol for propranolol in patients with heart failure

FUNDAMENTO: Grandes estudos clínicos empregando os betabloqueadores carvedilol, metoprolol, bisoprolol e nebivolol, demonstraram melhora da sobrevida e dos sintomas em pacientes com insuficiência cardíaca. Apesar da falta de evidências científicas, é plausível que o efeito benéfico seja extensível a outros betabloqueadores. OBJETIVO: Avaliar em pacientes com insuficiência cardíaca o impacto da substituição do carvedilol por propranolol sobre a função ventricular esquerda, capacidade funcional, qualidade de vida, níveis pressóricos e controle autonômico cardíaco. MÉTODOS: Vinte e nove pacientes com terapêutica medicamentosa otimizada incluindo doses máximas toleradas de carvedilol foram divididos em dois grupos: substituição de carvedilol por propranolol (n = 15) e manutenção de carvedilol (n = 14). Na condição basal, e após 6 meses, foram realizadas avaliações clínica e laboratorial com: ventriculografia nuclear, ecocardiografia, questionário de Minnesota, teste de caminhada, MAPA e Holter. RESULTADOS: As características laboratoriais e demográficas foram similares nos dois grupos na avaliação inicial. Ajuste individualizado da dose do propranolol garantiu grau semelhante de betabloqueio avaliado pela frequência cardíaca em repouso e reserva cronotrópica. A dose média de propranolol usada foi 109 ± 43 mg/dia. Apenas um paciente apresentou intolerância ao propranolol com retorno do carvedilol. Foi registrado um óbito no grupo propranolol. A fração de ejeção apresentou aumento significativo no grupo propranolol. As demais variáveis cardiovasculares não sofreram modificações significativas após troca do betabloqueador. CONCLUSÃO: Nossos resultados indicam que a substituição do carvedilol por propranolol em pacientes com insuficiência cardíaca não está associada à deterioração da fração de ejeção, da capacidade funcional, da qualidade de vida e das variáveis cardiovasculares de controle pressórico e autonômico.

BACKGROUND: Large clinical trials using the betablockers carvedilol, metoprolol, bisoprolol and nebivolol have demonstrated improvement of survival and symptoms in patients with heart failure. Despite the lack of scientific evidence, it is plausible that their beneficial effects are extensible to other betablockers. OBJECTIVE: To evaluate the impact of the replacement of carvedilol for propranolol on left ventricular function, functional capacity, quality of life, pressure levels, and cardiac autonomic control in patients with heart failure. METHODS: Twenty nine patients receiving optimized drug therapy including maximum tolerated doses of carvedilol were divided into two groups: replacement of carvedilol for propranolol (n = 15) and continued carvedilol (n = 14). At baseline and 6 months later, clinical and laboratorial assessments were carried out with radionuclide ventriculography, echocardiography, Minnesota questionnaire, walk test, APBM and Holter monitoring. RESULTS: The clinical and demographic characteristics were similar in the two groups at baseline. Individualized propranolol dose adjustment ensured a similar degree of beta-blockade, as assessed by resting heart rate and chronotropic reserve. The mean propranolol dose used was 109 ± 43 mg/day. Only one patient presented with intolerance to propranolol, thus carvedilol was reintroduced. One death was recorded in group propranolol. Ejection fraction significantly increased in the propranolol group. No significant change was observed in the other cardiovascular variables after betablocker replacement. CONCLUSION: Our results indicate that replacement of carvedilol for propranolol in patients with heart failure is not associated with deterioration of the ejection fraction, functional capacity, quality of life, and other cardiovascular variables related to autonomic and blood pressure control., PP.0-0).

FUNDAMENTO: Grandes estudios clínicos empleando los betabloqueantes carvedilol, metoprolol, bisoprolol y nebivolol, demostraron mejora de la sobrevida y de los síntomas en pacientes con insuficiencia cardíaca. A pesar de la falta de evidencias científicas, es plausible que el efecto benéfico sea extensible a otros betabloqueantes. OBJETIVO: Evaluar en pacientes con insuficiencia cardíaca el impacto de la sustitución del carvedilol por propranolol sobre la función ventricular izquierda, capacidad funcional, calidad de vida, niveles presóricos y control autonómico cardíaco. MÉTODOS: Veintinueve pacientes con terapéutica medicamentosa optimizada incluyendo dosis máximas toleradas de carvedilol fueron divididos en dos grupos: sustitución de carvedilol por propranolol (n=15) y manutención de carvedilol (n=14). En la condición basal, y después de 6 meses, fueron realizadas evaluaciones clínica y de laboratorio con: ventriculografía nuclear, ecocardiografía, cuestionario de Minnesota, test de caminata, MAPA y Holter. RESULTADOS: Las características de laboratorio y demográficas fueron similares en los dos grupos en la evaluación inicial. Un ajuste individualizado de la dosis de propranolol garantizó grado semejante de betabloqueo evaluado por la frecuencia cardíaca en reposo y reserva cronotrópica. La dosis media de propranolol usada fue 109 1 43 mg/día. Apenas un paciente presentó intolerancia al propranolol con retorno al carvedilol. Fue registrado un óbito no grupo propranolol. La fracción de eyección presentó aumento significativo en el grupo propranolol. Las demás variables cardiovasculares no sufrieron modificaciones significativas después del cambio de betabloqueante. CONCLUSIÓN: Nuestros resultados indican que la sustitución del carvedilol por propranolol en pacientes con insuficiencia cardíaca no está asociada al deterioro de la fracción de eyección, de la capacidad funcional, de la calidad de vida y de las variables cardiovasculares de control presórico y autonómico

Replacement of carvedilol for propranolol in patients with heart failure.

BACKGROUND: Large clinical trials using the betablockers carvedilol, metoprolol, bisoprolol and nebivolol have demonstrated improvement of survival and symptoms in patients with heart failure. Despite the lack of scientific evidence, it is plausible that their beneficial effects are extensible to other betablockers. OBJECTIVE: To evaluate the impact of the replacement of carvedilol for propranolol on left ventricular function, functional capacity, quality of life, pressure levels, and cardiac autonomic control in patients with heart failure. METHODS: Twenty nine patients receiving optimized drug therapy including maximum tolerated doses of carvedilol were divided into two groups: replacement of carvedilol for propranolol (n = 15) and continued carvedilol (n = 14). At baseline and 6 months later, clinical and laboratorial assessments were carried out with radionuclide ventriculography, echocardiography, Minnesota questionnaire, walk test, APBM and Holter monitoring. RESULTS: The clinical and demographic characteristics were similar in the two groups at baseline. Individualized propranolol dose adjustment ensured a similar degree of beta-blockade, as assessed by resting heart rate and chronotropic reserve. The mean propranolol dose used was 109 +/- 43 mg/day. Only one patient presented with intolerance to propranolol, thus carvedilol was reintroduced. One death was recorded in group propranolol. Ejection fraction significantly increased in the propranolol group. No significant change was observed in the other cardiovascular variables after betablocker replacement. CONCLUSION: Our results indicate that replacement of carvedilol for propranolol in patients with heart failure is not associated with deterioration of the ejection fraction, functional capacity, quality of life, and other cardiovascular variables related to autonomic and blood pressure control., PP.0-0).

Ventricular tachycardia in Chagas' disease: a comparison of clinical, angiographic, electrophysiologic and myocardial perfusion disturbances between patients presenting with either sustained or nonsustained forms.

UNLABELLED: Ventricular tachycardia (VT) is common among patients with Chagas' heart disease but the ultimate mechanisms responsible for its sustained and nonsustained forms are not understood. This study aimed at determining which factors differentiate between patients with sustained (S-VT) and nonsustained VT (NS-VT). Fifty-six consecutive chagasic patients with VT were prospectively selected: 28 patients with spontaneous S-VT and 28 patients with NS-VT. The patients underwent clinical, angiographic, electrophysiologic and myocardial perfusion examination. Syncope episodes (S-VT: 43% versus NS-VT: 11%, p = 0.007) and induction of S-VT by programmed ventricular stimulation (S-VT: 89% versus NS-VT: 7%, p = 0.001) were significantly more frequent in S-VT patients. Evidence of a scar-related reentry was observed in all 24 S-VT patients who underwent endocardial mapping for attempted radiofrequency ablation of 33 VTs. Overall, 29 VTs arose from the LV (88%) and 4 VTs arose from the RV (12%). Among these, 27 VTs (82%) were related to LV inferolateral scar, 2 VTs (6%) were related to LV apical scar, and 4 VTs (12%) were related to RV scars. A significantly higher prevalence of wall motion abnormalities (S-VT: 82% versus NS-VT: 46%, p = 0.005) and myocardial perfusion defects (basal segments, S-VT: 95.5% versus NS-VT: 44%, p = 0.001) was documented within the LV inferior and/or posterolateral regions in S-VT patients compared to NS-VT. IN CONCLUSION: (a) VT may arise from various regions in both ventricles, but LV inferolateral scar is the main source of S-VT reentrant circuits; (b) there is good topographic correlation between myocardial perfusion, wall motion abnormalities and areas that originate S-VT; (c) although to a lesser extent, wall motion and perfusion defects also occur in a relevant proportion of chagasics with NS-VT.

Prediction of left ventricular wall motion recovery after acute myocardial infarction by Tl-201 gated SPECT: incremental value of integrated contractile reserve assessment.

BACKGROUND: This investigation tested the application of low-dose dobutamine (LDD) gated single photon emission computed tomography (SPECT) with thallium 201 for myocardial viability detection early after acute myocardial infarction (AMI). METHODS AND RESULTS: Thirty-two hemodynamically stable post-AMI patients (aged 55 +/- 5 years [mean +/- SEM]; 20 men) who were exhibiting regional left ventricular dysfunction underwent stress-redistribution Tl-201 scanning within 4 to 8 days, followed by 2 additional gated SPECT acquisitions after Tl-201 reinjection, at rest and during LDD. A visual 5-point score was computed for segmental radiotracer uptake (0, normal; 4, absent) and a 4-point score for left ventricular wall motion (1, normal; 4, dyskinesis). Predominant viable myocardium in dyssynergic regions was predicted by a mean Tl-201 uptake score of 2 or less or ischemic area of 30% or greater. These indices showed a significant association with wall motion improvement in follow-up echocardiographic studies (overall accuracy = 0.69, sensitivity = 0.93, and specificity = 0.50). Regarding the response to LDD stimulus, an increase in mean wall motion score of 30% or greater was predictive of predominant viable myocardium. Contractile reserve assessment yielded a significant increment in the predictive accuracy for function recovery (overall accuracy = 0.84, sensitivity = 0.71, and specificity = 0.94). CONCLUSIONS: Evaluation of contractile reserve by means of LDD gated SPECT with Tl-201 is safely feasible early after AMI, with incremental value over perfusion assessment alone for myocardial viability detection.

Infarto agudo do miocárdio: princípios básicos do tratamento clínico / Acude myocardial infarction: current management

Procedeu-se a revisäo sistematizada das formas de tratamento atualmente aplicadas em pacientes com infarto agudo do miocárdio. As variadas intervençöes terapêuticas foram analisadas criticamente sob o enfoque dos princípios fisiopatológicos que as embasam. De fundamental relevância foram consideradas as evidências de reduçäo de morbidade e mortalidade, dependente de cada intervençäo terapêutica, resultantes de análises estatísticas coletivas de estudo globalmente focalizados, ou dos chamados mega-ensaios multicêntricos prospectivamente concebidos. A luz dessas observaçöes, säo plenamente justificadas as condutas de internaçäo em unidades coronariana, de analgesia, sedaçäo, repouso, suplementaçäo de oxigênio, como medidas gerais, aplicáveis a todos os pacientes nas primeiras 24-48 horas do infarto miocárdio. Administraçäo profilática de lidocaína e anticoagulaçäo näo devem mais ser consideradas indiscriminadamente, mas devem ser implementadas em circunstâncias específicas, com base na definiçäo do benefício/risco individualmente avaliado. O uso precoce (nas primeiras 4-6 horas) de nitratos, bloqueadores beta-adrenérgicos e de trombolíticos farmacológicos parece hoje plenamente justificado no sentido de reduzir-se a área de necrose miocárdica. angioplastia coronariana transluminal, embora bastante efetiva como agente de reperfusiao mecânica, tem emprego restrito, em virtude de limitaçöes logísticas, como intervençäo primária; pode ser necessária em condiçöes de insucesso de trombólise farmacológica, quando há extensas áres de miocárdio em risco. Revascularizaçäo cirúrgica é presentemente reservada para o tratamento de instabilizaçäo hemodinâmica consequente a insucesso com as tentativas clínicas de reperfusäo, e correçäo de complicaçöes mecânicas como insuficiência mitral, rotura septal. A identificaçäo precoce de pacientes com alto risco de acidentes isquêmicos adicionais tornou-se conduta hoje mandatória, inclusive por meio de testes ergométricos submáximos, preferencialmente com tálio-201, antes da alta hospitalar